Regeneron Pharmaceuticals (REGN) Invested Capital (2017 - 2025)

Regeneron Pharmaceuticals' Invested Capital history runs 8 years deep, the most recent figure standing at $720.0 million for Q4 2025.

• On a quarterly basis, Invested Capital changed 0.0% year-over-year to $720.0 million in Q4 2025; TTM through Mar 2026 was $720.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $720.0 million, changed 0.0% from the prior year.
• Invested Capital held at $720.0 million in Q4 2025 per REGN's latest filing, from $720.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $720.0 million in Q1 2022 and bottomed at $719.7 million in Q4 2021.
• The 5-year median for Invested Capital is $720.0 million (2022), against an average of $720.0 million.
• Across the five-year window, Invested Capital grew 0.35% in 2021 and changed 0.0% in 2023, its largest moves.
• Year by year, Invested Capital stood at $719.7 million in 2021, then grew by 0.04% to $720.0 million in 2022, then changed by 0.0% to $720.0 million in 2023, then changed by 0.0% to $720.0 million in 2024, then changed by 0.0% to $720.0 million in 2025.
• Per Business Quant, the three latest REGN Invested Capital figures stand at $720.0 million (Q4 2025), $720.0 million (Q4 2024), and $720.0 million (Q4 2023).